Understanding cachexia as a cancer metabolism syndrome

被引:387
作者
Porporato, P. E. [1 ]
机构
[1] Catholic Univ Louvain, IREC, Pole Pharmacol, Ave Emmanuel Mounier 52 Box B1-53-09, B-1200 Brussels, Belgium
基金
欧洲研究理事会;
关键词
TUMOR-NECROSIS-FACTOR; UBIQUITIN-PROTEASOME PATHWAY; GUT BARRIER DYSFUNCTION; SKELETAL-MUSCLE; GLUCOSE-METABOLISM; PANCREATIC-CANCER; GENE-EXPRESSION; INSULIN-RESISTANCE; MESSENGER-RNA; GASTROINTESTINAL CANCER;
D O I
10.1038/oncsis.2016.3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metabolic reprogramming occurs in tumors to foster cancer cell proliferation, survival and metastasis, but as well at a systemic level affecting the whole organism, eventually leading to cancer cachexia. Indeed, as cancer cells rely on external sources of nitrogen and carbon skeleton to grow, systemic metabolic deregulation promoting tissue wasting and metabolites mobilization ultimately supports tumor growth. Cachectic patients experience a wide range of symptoms affecting several organ functions such as muscle, liver, brain, immune system and heart, collectively decreasing patients' quality of life and worsening their prognosis. Moreover, cachexia is estimated to be the direct cause of at least 20% of cancer deaths. The main aspect of cachexia syndrome is the unstoppable skeletal muscle and fat storage wasting, even with an adequate caloric intake, resulting in nutrient mobilization - both directly as lipid and amino acids and indirectly as glucose derived from the exploitation of liver gluconeogenesis - that reaches the tumor through the bloodstream. From a metabolic standpoint, cachectic host develops a wide range of dysfunctions, from increased insulin and IGF-1 resistance to induction of mitochondrial uncoupling proteins and fat tissue browning resulting in an increased energy expenditure and heat generation, even at rest. For a long time, cachexia has been merely considered an epiphenomenon of end-stage tumors. However, in specific tumor types, such as pancreatic cancers, it is now clear that patients present markers of tissue wasting at a stage in which tumor is not yet clinically detectable, and that host amino acid supply is required for tumor growth. Indeed, tumor cells actively promote tissue wasting by secreting specific factors such as parathyroid hormone-related protein and micro RNAs. Understanding the molecular and metabolic mediators of cachexia will not only advance therapeutic approaches against cancer, but also improve patients' quality of life.
引用
收藏
页码:e200 / e200
页数:10
相关论文
共 199 条
[91]   SYSTEMIC ADMINISTRATION OF CILIARY NEUROTROPHIC FACTOR INDUCES CACHEXIA IN RODENTS [J].
HENDERSON, JT ;
SENIUK, NA ;
RICHARDSON, PM ;
GAULDIE, J ;
RODER, JC .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (06) :2632-2638
[92]   TUMOR NECROSIS FACTOR-MEDIATED HYPOALBUMINEMIA IN RABBITS [J].
HENNIG, B ;
HONCHEL, R ;
GOLDBLUM, SE ;
MCCLAIN, CJ .
JOURNAL OF NUTRITION, 1988, 118 (12) :1586-1590
[93]   Both Acyl and Des-Acyl Ghrelin Regulate Adiposity and Glucose Metabolism via Central Nervous System Ghrelin Receptors [J].
Heppner, Kristy M. ;
Piechowski, Carolin L. ;
Mueller, Anne ;
Ottaway, Nickki ;
Sisley, Stephanie ;
Smiley, David L. ;
Habegger, Kirk M. ;
Pfluger, Paul T. ;
DiMarchi, Richard ;
Biebermann, Heike ;
Tschoep, Matthias H. ;
Sandoval, Darleen A. ;
Perez-Tilve, Diego .
DIABETES, 2014, 63 (01) :122-131
[94]  
HOLROYDE CP, 1984, CANCER RES, V44, P5910
[95]  
HOLROYDE CP, 1975, CANCER RES, V35, P3710
[96]   The role of insulin resistance in the development of muscle wasting during cancer cachexia [J].
Honors, Mary A. ;
Kinzig, Kimberly P. .
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2012, 3 (01) :5-11
[97]   TUMOR-NECROSIS-FACTOR-ALPHA INHIBITS SIGNALING FROM THE INSULIN-RECEPTOR [J].
HOTAMISLIGIL, GS ;
MURRAY, DL ;
CHOY, LN ;
SPIEGELMAN, BM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) :4854-4858
[98]   INVESTIGATION OF THE CAUSE OF DEATH FROM CANCER [J].
HOUTEN, L ;
REILLEY, AA .
JOURNAL OF SURGICAL ONCOLOGY, 1980, 13 (02) :111-116
[99]  
INCULET RI, 1987, JNCI-J NATL CANCER I, V79, P1039
[100]   PHASE-I TRIAL OF INTRAMUSCULARLY ADMINISTERED TUMOR NECROSIS FACTOR IN PATIENTS WITH ADVANCED CANCER [J].
JAKUBOWSKI, AA ;
CASPER, ES ;
GABRILOVE, JL ;
TEMPLETON, MA ;
SHERWIN, SA ;
OETTGEN, HF .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (03) :298-303